{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T07:28:14Z","timestamp":1743924494620,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T00:00:00Z","timestamp":1547856000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s00280-019-03772-y","type":"journal-article","created":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T02:45:40Z","timestamp":1547865940000},"page":"673-679","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Influence of oral magnesium-containing supplement and antacid administration on hypomagnesemia induced by panitumumab"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2478-0190","authenticated-orcid":false,"given":"Junya","family":"Sato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rei","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiro","family":"Sino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,19]]},"reference":[{"key":"3772_CR1","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/bjc.2016.309","volume":"115","author":"TW Kim","year":"2014","unstructured":"Kim TW, Elme A, Kusic Z et al (2014) A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer. Br J Cancer 115:1206\u20131214","journal-title":"Br J Cancer"},{"key":"3772_CR2","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S1470-2045(14)70118-4","volume":"15","author":"TJ Price","year":"2014","unstructured":"Price TJ, Peeters M, Kim TW et al (2014) Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 15:569\u2013579","journal-title":"Lancet Oncol"},{"key":"3772_CR3","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/annonc\/mdu141","volume":"25","author":"JY Douillard","year":"2014","unstructured":"Douillard JY, Siena S, Cassidy J et al (2014) Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 25:1346\u20131355","journal-title":"Ann Oncol"},{"key":"3772_CR4","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3816\/CCC.2006.n.033","volume":"6","author":"M Fakih","year":"2006","unstructured":"Fakih M, Wilding G, Lombardo J (2006) Cetuximab-induced hypomagnesemia in patients with colorectal cancer. Clin Colorectal Cancer 6:152\u2013156","journal-title":"Clin Colorectal Cancer"},{"key":"3772_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S1470-2045(07)70108-0","volume":"8","author":"S Tejpar","year":"2007","unstructured":"Tejpar S, Piessevaux H, Claes K, Piront P, Hoenderop JG, Verslype C, Van Cutsem E (2007) Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 8:387\u2013394","journal-title":"Lancet Oncol"},{"key":"3772_CR6","first-page":"74","volume":"22","author":"M Fakih","year":"2008","unstructured":"Fakih M (2008) Management of anti-EGFR-targeting monoclonal antibody-induced hypomagnesemia. Oncology (Williston Park) 22:74\u201376","journal-title":"Oncology (Williston Park)"},{"key":"3772_CR7","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1093\/jnci\/dji242","volume":"97","author":"D Schrag","year":"2005","unstructured":"Schrag D, Chung KY, Flombaum C, Saltz L (2005) Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 97:1221\u20131224","journal-title":"J Natl Cancer Inst"},{"key":"3772_CR8","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1248\/yakushi.16-00020","volume":"137","author":"Y Yoshimura","year":"2017","unstructured":"Yoshimura Y, Fujisaki K, Yamamoto T, Shinohara Y (2017) Pharmacokinetic studies of orally administered magnesium oxide in rats. Yakugaku Zasshi 137:581\u2013587","journal-title":"Yakugaku Zasshi"},{"key":"3772_CR9","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/jphp.12600","volume":"68","author":"H Ibuka","year":"2016","unstructured":"Ibuka H, Ishihara M, Suzuki A, Kagaya H, Shimizu M, Kinosada Y, Itoh Y (2016) Antacid attenuates the laxative action of magnesia in cancer patients receiving opioid analgesic. J Pharm Pharmacol 68:1214\u20131221","journal-title":"J Pharm Pharmacol"},{"key":"3772_CR10","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00228-014-1694-x","volume":"70","author":"M Yamasaki","year":"2014","unstructured":"Yamasaki M, Funakoshi S, Matsuda S, Imazu T, Takeda Y, Murakami T, Maeda Y (2014) Interaction of magnesium oxide with gastric acid secretion inhibitors in clinical pharmacotherapy. Eur J Clin Pharmacol 70:921\u2013924","journal-title":"Eur J Clin Pharmacol"},{"key":"3772_CR11","first-page":"1873","volume":"36","author":"Y Yamamoto","year":"2016","unstructured":"Yamamoto Y, Watanabe K, Tsukiyama I, Yabushita H, Matsuura K, Wakatsuki A (2016) Hydration with 15\u00a0mEq magnesium is effective at reducing the risk for cisplatin-induced nephrotoxicity in patients receiving cisplatin (\u2265\u200950\u00a0mg\/m2) combination chemotherapy. Anticancer Res 36:1873\u20131877","journal-title":"Anticancer Res"},{"key":"3772_CR12","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1016\/j.ejca.2008.08.005","volume":"44","author":"L Bodnar","year":"2008","unstructured":"Bodnar L, Wcislo G, Gasowska-Bodnar A, Synowiec A, Szarlej-Wcis\u0142o K, Szczylik C (2008) Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. Eur J Cancer 44:2608\u20132614","journal-title":"Eur J Cancer"},{"key":"3772_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/bjc.1986.147","volume":"54","author":"JC Willox","year":"1986","unstructured":"Willox JC, McAllister EJ, Sangster G, Kaye SB (1986) Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial. Br J Cancer 54:19\u201323","journal-title":"Br J Cancer"},{"key":"3772_CR14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/00045391-200109000-00008","volume":"8","author":"VV Ranade","year":"2001","unstructured":"Ranade VV, Somberg JC (2001) Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans. Am J Ther 8:345\u2013357","journal-title":"Am J Ther"},{"key":"3772_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1080\/07315724.1990.10720349","volume":"9","author":"JS Lindberg","year":"1990","unstructured":"Lindberg JS, Zobitz MM, Poindexter JR, Pak CY (1990) Magnesium bioavailability from magnesium citrate and magnesium oxide. J Am Coll Nutr 9:48\u201355","journal-title":"J Am Coll Nutr"},{"unstructured":"FDA Drug Safety Communication. Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs). \n                    https:\/\/www.fda.gov\/drugs\/drugsafety\/ucm245011.htm\n                    \n                  . Accessed 7 Dec 2018 (Updated 8 Apr 2017)","key":"3772_CR16"},{"key":"3772_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1370\/afm.1243","volume":"9","author":"CS Eom","year":"2011","unstructured":"Eom CS, Park SM, Myung SK, Yun JM, Ahn JS (2011) Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam Med 9:257\u2013267","journal-title":"Ann Fam Med"},{"key":"3772_CR18","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0016-5085(94)94341-9","volume":"106","author":"HS Merki","year":"1994","unstructured":"Merki HS, Wilder-Smith CH (1994) Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing? Gastroenterology 106:60\u201364","journal-title":"Gastroenterology"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-019-03772-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03772-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03772-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T09:22:28Z","timestamp":1580721748000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-019-03772-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,19]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["3772"],"URL":"https:\/\/doi.org\/10.1007\/s00280-019-03772-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2019,1,19]]},"assertion":[{"value":"28 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}